Prexa Pharmaceuticals

Prexa Pharmaceuticals develops small molecule monoamine reuptake inhibitors as a treatment for ADHD, depression and Parkinson’s disease.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinsonâ€s disease. Prexaâ€s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexaâ€s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexaâ€s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.